Navigation Links
Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
Date:6/24/2008

xecutive officer. "Our partners at Astellas are the market leaders in the MPI market and are very well positioned for commercial success."

CV Therapeutics owns the rights for regadenoson outside of North America and currently expects to submit a marketing authorization application for the product to the European Medicines Agency by the end of 2008.

Astellas Pharma US, Inc. / CV Therapeutics Inc. Collaboration

Under a license and collaboration agreement providing Astellas with exclusive North American rights to Lexiscan(TM) (regadenoson) injection, CV Therapeutics completed the development program and Astellas is responsible for all commercial activities for the product in North America. Under the arrangement, Astellas paid CV Therapeutics a $7 million milestone upon submission of the new drug application to the FDA, and a $12 million milestone in April 2008. Astellas also reimburses CV Therapeutics for 75 percent of development costs. CV Therapeutics will receive a royalty on product sales of Lexiscan(TM) (regadenoson) injection, and may receive a royalty on another Astellas product.

About Lexiscan(TM) (regadenoson) injection

Lexiscan(TM) is an A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide MPI studies in patients unable to undergo adequate exercise stress. Lexiscan(TM) was designed to produce coronary vasodilation and increase coronary blood flow by activation of the A2A adenosine receptor. Lexiscan(TM) is administered as a rapid bolus (approximately 10 seconds) with no dose adjustment required for body weight. Lexiscan(TM) should not be administered to patients with second- or third-degree AV block or sinus node dysfunction who do not have a functioning artificial pacemaker. Adenosine receptor agonists, including Lexiscan(TM), induce arterial vasodilation and hypotension. The risk of serious hypotension may be higher in patients with cardiac or cerebrovascular insufficiency. Comple
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. ADVENTRX Appoints Vice President of Commercialization
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
7. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
8. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
9. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
10. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
11. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... The Alliance for Safe Biologic ... European physicians at the "1 ST EuropaBio ... at the Spanish Ministry of Health, Social Services ... the Spanish Bioindustry Association (ASEBIO), included regulators from ... oncology and rheumatology societies, representatives from a hospital ...
(Date:11/26/2014)... Charlotte, NC (PRWEB) November 25, 2014 ... High Intensity Focused Ultrasound (HIFU) devices, recently participated ... “ Small Renal Mass 360° .” Key opinion ... and therapeutic advances related to small renal masses ... learn about different ablative technologies in hands-on labs. ...
(Date:11/26/2014)... Miles Holder, formerly of Micron Research and ... team as Sales/Marketing Manager. Mr. Holder has over 25 ... the graphite industry. , “We are thrilled to be ... Trinkley, VP of Market and Product Development for Graphel ... the graphite industry, along with his proven track record ...
(Date:11/26/2014)... , Nov. 25, 2014 Bio-Techne Corporation ... has appointed Robert Gavin to serve in ... the Protein Platforms Division.  Mr. Gavin will be responsible ... segment, which includes the ProteinSimple business acquired in July ... San Jose, California -based ProteinSimple develops ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... 2011 The New York Stem Cell Summit is releasing ... the press and the general public understand more accurately the ... the United States today. Approximately 1 million patients ... mid-1980s in the United States. Harvesting stem ...
... 2011 Renmatix , the leading producer of cellulosic sugars, ... fuels company Amyris , has joined the Renmatix Board of ... Year" by the Philadelphia Business Journal , will fill the ... Melo comes to the Renmatix Board of Directors with rare ...
... Sept. 13Researchers at Vanderbilt University have developed a new technique ... biological tissue at multiple points simultaneously, a method that could ... grow and change shape. UV lasers are a ... make incisions by vaporizing one point at a time in ...
Cached Biology Technology:New York Stem Cell Summit Issues Adult Stem Cell Fact Sheet 2Amyris Chief Joins Renmatix BoD, New CFO Added to Company 2
(Date:11/4/2014)... nature, the right amount of death at the right ... according to new research that could help in understanding ... stocks. , In a paper in the journal ... researcher and European colleagues conclude that the kind of ... loss of individuals, or mortality, depends on the size ...
(Date:11/4/2014)... A majority of Madagascar,s 101 species of lemurs are ... for the rainforests they call home. A new study ... can have on rainforest tree populations, which raises concerns ... the region,s rich biodiversity. , A large proportion of ... Lemurs in turn disperse the seeds of their ...
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Preterm, low birth-weight babies may need new hips in adulthood 2
... incredibly temperature sensitive and can perceive changes of as little ... 8th issue of the journal Cell , a Cell ... rise, but also coordinate an appropriate response -- activating hundreds ... about the way that their DNA is packaged. The ...
... gardening world it may have always been considered a fact, ... watering your garden in the midday sun can lead to ... in New Phytologist , provides an answer that not ... for forest fires and human sunburn. "The problem ...
... project E! 3184 Odysseus has developed systems to ... tumours or other pathologies, from MRI or CT-scans. The ... location, for consultation in real time just before surgery. ... with the best possible diagnostic support, before real surgery ...
Cached Biology News:How plants 'feel' the temperature rise 2Can a drop of water cause sunburn or fire? 2A virtual liver, a better chance of life 2A virtual liver, a better chance of life 3